IMWG publishes consensus on second primary malignancies in myeloma

The International Myeloma Working Group (IMWG) has published a consensus statement providing practical recommendations for managing myeloma patients who develop second primary malignanices (SPMs). Published in the Annals of Oncology, the group reviewed the latest evidence of possible host-, disease- and treatment-related risk factors for the development of SPMs in myeloma patients. They recommend that…


Study shows no link between response rates and survival in myeloma

Results of a meta-regression analysis have shown that, contrary to popular opinion, there is no association between conventional response outcomes, such as complete response (CR) or very good partial response (VGPR), and survival in newly diagnosed myeloma patients. Published recently in the European Journal of Haematology, the researchers explored the relationship between response to initial…


Key partnership formed to create the Myeloma Genome Project

Celgene, the Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences (UAMS) have announced that they have partnered to create the Myeloma Genome Project to compile high quality genetic and clinical data to improve diagnosis, prognosis and treatment for myeloma patients. The aim is to develop a strategy for classifying myeloma into subgroups…